TrialBone marrow transplantation2024

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.

Mónica Cabrero et al.PubMed ↗Publisher ↗

No numbers read from the abstract.